The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC) - PubMed (original) (raw)

Review

The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC)

Timothy D Wagner et al. Curr Drug Targets. 2010 Jan.

Abstract

Approximately one out of every three patients with non-small cell lung cancer (NSCLC) has locally advanced disease that is surgically unresectable. If their performance status allows, it is current practice to treat these patients with a combination of chemotherapy and external beam irradiation. There have been several studies supporting the addition of chemotherapy to radiation, particularly when delivered concurrently. There is debate over which treatment agents and schedules are most optimal, even with the most proven treatments delivering only modest results, with high rates of local and distant disease failure. Advances in imaging and radiation planning and delivery technology have allowed for the potential for improvement of the therapeutic ratio by reducing normal tissue exposure and ensuring for more precise delivery, while new systemic agents show promising activity in NSCLC. Pemetrexed is a pyrrolopyrimidine-based folate anti-metabolite that works by inhibiting a variety of enzymes of thymidylate and purine synthesis, thus leading to cell stasis and death. Similar to other cytotoxic antifolates, pemetrexed has been shown in pre-clinical study to act as an effective radiosensitizer. At present, it is being studied in phase I and II studies when combined with other systemic agents and radiation therapy in the treatment of locally advanced NSCLC, and the results have been promising. It has the advantage of allowing for relatively safe delivery of full systemic doses when combined other agents and radiation therapy, a distinction over combined modality treatments. Its efficacy, particularly in non-squamous NSCLC, in phase I and II studies has lead to investigations in the phase III setting where a more defined role for pemetrexed in locally advanced non-squamous NSCLC will potentially be defined. This review summarizes the use of combined modality treatment in locally advanced NSCLC, outlines recent advances in radiation planning and treatment, and reviews the current data on the use concurrent chemoradiation regimens featuring pemetrexed.

PubMed Disclaimer

Cited by

HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer.
Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu Z, Gomez D, O'Reilly M, Lin SH, Zhuang Y, Levy LB, Mohan R, Zhou H, Liao Z. Xu T, et al. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e229-35. doi: 10.1016/j.ijrobp.2012.03.032. Epub 2012 May 19. Int J Radiat Oncol Biol Phys. 2012. PMID: 22608953 Free PMC article.
Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors.
Lowery A, Onishko H, Hallahan DE, Han Z. Lowery A, et al. J Control Release. 2011 Feb 28;150(1):117-24. doi: 10.1016/j.jconrel.2010.11.006. Epub 2010 Nov 12. J Control Release. 2011. PMID: 21075152 Free PMC article.
Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.
Choy H, Schwartzberg LS, Dakhil SR, Garon EB, Gerber DE, Choksi JK, Govindan R, Peng G, Koustenis A, Treat J, Obasaju C. Choy H, et al. J Thorac Oncol. 2013 Oct;8(10):1308-16. doi: 10.1097/JTO.0b013e3182a02546. J Thorac Oncol. 2013. PMID: 23981966 Free PMC article. Clinical Trial.
Inhibitory effect of _trans_-ferulic acid on proliferation and migration of human lung cancer cells accompanied with increased endogenous reactive oxygen species and β-catenin instability.
Fong Y, Tang CC, Hu HT, Fang HY, Chen BH, Wu CY, Yuan SS, Wang HD, Chen YC, Teng YN, Chiu CC. Fong Y, et al. Chin Med. 2016 Oct 1;11:45. doi: 10.1186/s13020-016-0116-7. eCollection 2016. Chin Med. 2016. PMID: 27733866 Free PMC article.
A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer.
Sun M, Zhou T, Fang X, Wang D, Pang H, Chen Y, Hu K. Sun M, et al. Medicine (Baltimore). 2020 Aug 14;99(33):e21626. doi: 10.1097/MD.0000000000021626. Medicine (Baltimore). 2020. PMID: 32872022 Free PMC article.

The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC) - PubMed (original) (raw)